pharmaceutical

Market Update 09-29-09

As expected, the Fed decided not to make any significant changes to its policies last week, keeping the interest rate at virtually zero. Additionally, the Fed announced the continuation of its Treasury buyback program, set to end in October, while deciding to slow down the pace of purchasing agency debt and mortgage backed securities – now set to be completed in March of 2010, rather than by year’s end as originally planned.
 
While acknowledging improvements in the financial markets and the housing sector, the FOMC statement sounded more cautious regarding consumer spending. No wonder – the consumer is being constrained by ongoing job losses, little income growth, lower household wealth and tight credit.
 
The fact that the Federal Reserve intends to keep interest rates at the lowest level possible for an indefinite amount of time is another indication that the economy is still very fragile. We are concerned that the Fed doesn’t appear to have any exit strategy in place as inflation potentially could come on very quickly, brought in big part by the loose monetary policy implemented around the world.
 
Oil ended last week at about $66 per barrel, falling over 8 percent last week. This was the largest weekly drop in two months, pointing to still weak energy demand and again confirming that recovery isn’t going to happen overnight.
Read more...

Updating the Best from the Brainiest

All the stocks in FundFinds remain buys

 
FundFinds is a stock portfolio with a difference. We don’t look just for stocks we like—we first look for funds we like and then seek out the newest, or biggest, or most unusual of their holdings. Next we evaluate those holdings using our own stringent criteria. If they make the grade, they join FundFinds.
 
Using this approach, which lets us benefit from the expertise of top fund managers, we’ve accumulated a diversified group of 16 stocks. They all remain buys.
 
Our first picks, from Sequoia fund, were giant pharmaceutical chain Walgreen and rug maker Mohawk Industries.
Read more...

Looking Good: Allergan Gets the Vision Thing Right

It leads in eye health care and controls Botox, two sure growth areas

 
You can make a lot of money investing in health care stocks—but only if you focus on those that tap into long-term trends. These are the ones that will see their revenues and profits soar year after year.
 
For instance, don’t buy a drug company whose main product line is antibiotics, no matter how vital and life-saving, because people use antibiotics only for those short periods when they are sick, and there’s no reason to think there will be a great and steady surge in their use. Instead, find a company that makes the drugs that people use chronically, day in and day out, and that ever larger numbers of people will be demanding.
 
Two of the surest long-term health-related trends are rising longevity—i.e., an aging population—and, sad to say, obesity. People are living longer, and they’re getting fatter. As we explain below, these trends, together, relate to a third trend: the fast-growing incidence of eye disease. Drug companies with a franchise in the eye health area will have many years of torrid growth ahead.
Read more...

Quality at a Discount

ICAP scoops up a lagging oil company and a drug maker

 
On the preceding page, in recognition of the rising level of insecurity in the world, we urged fund investors to make sure they own at least one large-cap growth fund. By the same token, we were eager to add a high-quality large-cap stock or two to our Fund Finds portfolio. As we searched, we stumbled upon a relatively young, small five star-rated Large Cap Value fund: ICAP Select Equity fund (ICSLX). With just a little more than $140 million under management, the fund has been an outstanding performer. It is in the top 10 percent for the category year to date and in the top 11 percent for the past five-year period. The fund selects its holdings from a group of 450 large-cap U.S. and European names, focusing on stocks with attractive valuations, consistent to improving earnings, and clear catalysts for growth, such as new product launches. Recently the fund was featured in an article “Great Funds at Bargain Prices” in SmartMoney.com as one of 58 actively managed funds that have delivered impressive returns at a low cost over the past five years.
 
We’re not recommending that our subscribers buy ICAP Select Equity fund itself, though, for two reasons.
Read more...

A Media/Education Leader, Generic Drugs

Our new picks profit from rapid growth in two different age categories

 
We are selling one stock and buying two others. The net result: a portfolio better attuned to demographic trends and lighter in financial services, an area slated to become more vulnerable as the economic cycle progresses and interest rate hikes grow more likely.
 
Our sale is Bank of New York (reported on our web site). We still like the company, and at some point it could make its way back into our portfolio. We’re selling only because there are even better opportunities elsewhere, not because we’ve lost faith in the company’s underlying fundamentals.
 
Our two additions are the Washington Post (discussed last issue in Sector Sense) and Teva Pharmaceuticals. Both are strong beneficiaries of the demographic trends presented in the preceding article.
Read more...

Fourth-Quarter Updates

The latest news and results from our shorts and longs

 
With year-end results pouring in, this seemed a good time for some updates. MIM Corp. reported an exceptional fourth quarter despite its disappointments over TennCare and the product Synagis. Overall revenues rose 26 percent, to $150 million. More significant, the company announced it has acquired Natural Living, a New York City-based specialty pharmaceutical company. This expands MIM’s presence in the important New York tristate area. The stock remains a favorite.
 
Cambrex reported fourth-quarter income from continuing operations of $6.1 million, or $0.23 per share. Over the last few months the company has dramatically refocused its business by selling its Rutherford Chemical division and changing its reporting segments to Human Health, BioProducts, and BioPharma. Now most of Cambrex’s revenues come from providing products to the pharmaceutical and life sciences industries. We expect its Human Health division to grow by 8-10 percent as the company introduced 22 new products in 2003, including Forest Labs’ Memantine (Namenda).
Read more...

Let’s Hear it for Health

Strong vital signs for a drug benefits manager and a hearing care provider

 
We love buying growth industries, or growth stocks, when they’re out of favor. By holding onto them patiently, you ultimately benefit from growth in earnings and expanding P/Es alike as Wall Street falls in love with the stocks all over again.
 
Right now, with investors busy chasing technology stocks, health care is being spurned. But health care is an undeniable growth area: people are living longer, baby boomers are aging, and pharmaceuticals and various medical products are becoming ever more technologically sophisticated.
 
One stock positioned to benefit is MIM Corp., a pharmacy benefit management (PBM) and specialty pharmaceutical company that partners with managed care organizations and health care providers to control pre-scription drug costs.
Read more...

WHAT THEY’RE THINKING

Byron Wien: Prophet of Profits

 
Everybody makes year-ahead predictions about the market. But people who are actually right much of the time are rare indeed. Morgan Stanley sage Byron Wien is one of those rare prophets whom it pays to heed.
 
Wien tries to bet against the consensus with an annual list of 10 prospective events he believes have a better than 50 percent chance of happening despite going against conventional Street wisdom. His list for 2004 is his 18th consecutive go at this endeavor, and while we haven’t kept records, our sense is that the results from last year’s forecasts were pretty typical. A year ago Wien predicted big gains for U.S. stocks, Japanese stocks, Brazilian stocks, homebuilders, and oil and oil-related investments. The stocks he expected would benefit from these trends climbed an average 50 percent, more than double the S&P 500’s gains.
 
Thus we were eager to see his predictions for 2004—and gratified that many of them coincided with our own view of the world. For starters, Wien is predicting $40 oil, $500 gold, and $8 silver as well as a strong stock market.
Read more...